Georgia Poison Center Reports 655 GLP-1 Calls So Far in 2026

Category:

• Published:

News Now Georgia logo. No verified story-specific photograph was available.

Calls to the Georgia Poison Center involving GLP-1 drugs reached 655 so far in 2026, compared with 38 in 2021, executive director Dr. Gaylord Lopez said. He described the rise as about 1,600%. Over the past two years, roughly one in five GLP-1 calls involved unapproved products sold through what is known as the gray market, Lopez said.

About 15% of people who contact the center about GLP-1 drugs need emergency-room evaluation, according to Lopez. He said dosing mistakes can include confusing milligrams with milliliters or using insulin syringes. Preparing products outside sterile conditions can also increase the risk of infection, he warned.

Hayley Lithwick said she started taking prescription Zepbound after talking with a doctor. The medication reduced her appetite, and she began exercising more. After a job change cost her insurance coverage, she said she could no longer afford the drug and began regaining weight.

Lithwick said she then bought retatrutide online for about $200, expecting a month’s supply. The product arrived as powder in vials, and the website carried a warning against human or veterinary use, consumption or application. She searched online for instructions to mix it herself.

After using the product, Lithwick reported sweating, nausea, an upset stomach and a fast heartbeat. She said she wanted to go to the hospital. She later estimated that she may have injected about twice the intended dose.

Retatrutide, which Eli Lilly is developing, remains in Phase 3 clinical trials and is not approved for public use. The company says the drug is not available to the public and cannot legally be sold for human use while it remains investigational. Lithwick said she has lost about 200 pounds overall.

Marcus Jones
News Now Georgia

Share This Story